Millennium Health announced that it has added three new genes to its Millennium PGT(SM) menu. The company also launched DestinationWell.com, an online tool offering consumers information about pharmacogenetics and how these tests can help patients understand the role that genetics plays in determining which prescription medications are right for them. Millennium PGT is a non-invasive genetic test that uses either a buccal or saliva-specimen to identify how a patient's genetic profile may impact response to certain medications.

The medication intelligence Millennium Health provides helps clinicians make more effective prescribing decisions personalised for each patient. The test results provide information to help clinicians determine the right drug and right dose for each patient. Millennium PGT analyzes up to 14 genes and provides clinically actionable interpretation for a broad list of medications in four key therapeutic areas: chronic pain, mental health, addiction and cardiovascular.

The three new genes offered include: DRD2 and HTR2C, relevant to antipsychotics and HLA-B*15:02, relevant to anticonvulsants. Millennium is the only pharmacogenetic test menu offering the unique combination of all three genes.